Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites
Identifieur interne : 000A39 ( Istex/Curation ); précédent : 000A38; suivant : 000A40Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites
Auteurs : Alexander Berchanski [Israël] ; Aviva Lapidot [Israël]Source :
- Journal of Molecular Modeling [ 1610-2940 ] ; 2009-03-01.
English descriptors
- KwdEn :
Abstract
Abstract: Aminoglycoside–arginine conjugates (AAC and APAC) are multi-target inhibitors of human immunodeficiency virus type-1 (HIV-1). Here, we predict new conjugates of neomycin with two arginine peptide chains binding at specific sites on neomycin [poly-arginine-neomycin-poly-arginine (PA-Neo-PA)]. The rationale for the design of such compounds is to separate two short arginine peptides with neomycin, which may extend the binding region of the CXC chemokine receptor type 4 (CXCR4). We used homology models of CXCR4 and unliganded envelope glycoprotein 120 (HIV-1IIIB gp120) and docked PA-Neo-PAs and APACs to these using a multistep docking procedure. The results indicate that PA-Neo-PAs spread over two negatively charged patches of CXCR4. PA-Neo-PA–CXCR4 complexes are energetically more favorable than AACs/APAC–CXCR4 complexes. Notably, our CXCR4 model and docking procedure can be applied to predict new compounds that are either inhibitors of gp120–CXCR4 binding without affecting stromal cell-derived factor 1α (SDF-1α) chemotaxis activity, or inhibitors of SDF-1α–CXCR4 binding resulting in an anti-metastasis effect. We also predict that PA-Neo-PAs and APACs can interfere with CD4–gp120 binding in unliganded conformation. Figure The r5-Neo-r5-CXCR4 complex. CXCR4 is shown in CPK representation. The negatively charged residues are shown in red and positively charged residues in blue. The r5-Neo-r5 is shown in stick representation, neomycin core is colored yellow and arginine moieties are colored magenta. Two negatively charged patches separated by neutral and positively charged residues are visible.
Url:
DOI: 10.1007/s00894-008-0401-1
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A39
Links to Exploration step
ISTEX:627E62E8DDCCBDD702E903064164A0C8357E4C4DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites</title>
<author><name sortKey="Berchanski, Alexander" sort="Berchanski, Alexander" uniqKey="Berchanski A" first="Alexander" last="Berchanski">Alexander Berchanski</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Organic Chemistry, The Weizmann Institute of Science, 76100, Rehovot, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Organic Chemistry, The Weizmann Institute of Science, 76100, Rehovot</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lapidot, Aviva" sort="Lapidot, Aviva" uniqKey="Lapidot A" first="Aviva" last="Lapidot">Aviva Lapidot</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Organic Chemistry, The Weizmann Institute of Science, 76100, Rehovot, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Organic Chemistry, The Weizmann Institute of Science, 76100, Rehovot</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>E-mail: aviva.lapidot@weizmann.ac.il</mods:affiliation>
<country wicri:rule="url">Israël</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:627E62E8DDCCBDD702E903064164A0C8357E4C4D</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1007/s00894-008-0401-1</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-WBV9ZP52-H/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A39</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A39</idno>
<idno type="wicri:Area/Istex/Curation">000A39</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites</title>
<author><name sortKey="Berchanski, Alexander" sort="Berchanski, Alexander" uniqKey="Berchanski A" first="Alexander" last="Berchanski">Alexander Berchanski</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Organic Chemistry, The Weizmann Institute of Science, 76100, Rehovot, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Organic Chemistry, The Weizmann Institute of Science, 76100, Rehovot</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lapidot, Aviva" sort="Lapidot, Aviva" uniqKey="Lapidot A" first="Aviva" last="Lapidot">Aviva Lapidot</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Organic Chemistry, The Weizmann Institute of Science, 76100, Rehovot, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Organic Chemistry, The Weizmann Institute of Science, 76100, Rehovot</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>E-mail: aviva.lapidot@weizmann.ac.il</mods:affiliation>
<country wicri:rule="url">Israël</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Journal of Molecular Modeling</title>
<title level="j" type="sub">Computational Chemistry - Life Sciences - Advanced Materials - New Methods</title>
<title level="j" type="abbrev">J Mol Model</title>
<idno type="ISSN">1610-2940</idno>
<idno type="eISSN">0948-5023</idno>
<imprint><publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="2009-03-01">2009-03-01</date>
<biblScope unit="volume">15</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="281">281</biblScope>
<biblScope unit="page" to="294">294</biblScope>
</imprint>
<idno type="ISSN">1610-2940</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1610-2940</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CXCR4/SDF-1α</term>
<term>HIV-1 entry inhibitors</term>
<term>Molecular modeling and docking</term>
<term>Poly-arginine aminoglycoside conjugates</term>
<term>Predicted compounds</term>
<term>gp120/CD4</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Aminoglycoside–arginine conjugates (AAC and APAC) are multi-target inhibitors of human immunodeficiency virus type-1 (HIV-1). Here, we predict new conjugates of neomycin with two arginine peptide chains binding at specific sites on neomycin [poly-arginine-neomycin-poly-arginine (PA-Neo-PA)]. The rationale for the design of such compounds is to separate two short arginine peptides with neomycin, which may extend the binding region of the CXC chemokine receptor type 4 (CXCR4). We used homology models of CXCR4 and unliganded envelope glycoprotein 120 (HIV-1IIIB gp120) and docked PA-Neo-PAs and APACs to these using a multistep docking procedure. The results indicate that PA-Neo-PAs spread over two negatively charged patches of CXCR4. PA-Neo-PA–CXCR4 complexes are energetically more favorable than AACs/APAC–CXCR4 complexes. Notably, our CXCR4 model and docking procedure can be applied to predict new compounds that are either inhibitors of gp120–CXCR4 binding without affecting stromal cell-derived factor 1α (SDF-1α) chemotaxis activity, or inhibitors of SDF-1α–CXCR4 binding resulting in an anti-metastasis effect. We also predict that PA-Neo-PAs and APACs can interfere with CD4–gp120 binding in unliganded conformation. Figure The r5-Neo-r5-CXCR4 complex. CXCR4 is shown in CPK representation. The negatively charged residues are shown in red and positively charged residues in blue. The r5-Neo-r5 is shown in stick representation, neomycin core is colored yellow and arginine moieties are colored magenta. Two negatively charged patches separated by neutral and positively charged residues are visible.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A39 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000A39 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:627E62E8DDCCBDD702E903064164A0C8357E4C4D |texte= Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |